Tharimmune Historical Income Statement
| THAR Stock | 1.90 0.01 0.53% |
Historical analysis of Tharimmune income statement accounts such as Other Operating Expenses of 11.4 M, Research Development of 4.3 M, Total Operating Expenses of 11.4 M or Total Other Income Expense Net of 164.4 K can show how well Tharimmune performed in making a profits. Evaluating Tharimmune income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tharimmune's future profits or losses.
Tharimmune Net Income |
|
Tharimmune |
About Tharimmune Income Statement Analysis
Tharimmune Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tharimmune shareholders. The income statement also shows Tharimmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Tharimmune Income Statement Chart
Add Fundamental
Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tharimmune. It is also known as Tharimmune overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Tharimmune income statement and is an important metric when analyzing Tharimmune profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Tharimmune's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tharimmune current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tharimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Tharimmune Stock, please use our How to Invest in Tharimmune guide.At this time, Tharimmune's Net Interest Income is relatively stable compared to the past year. As of 02/17/2025, Selling General Administrative is likely to grow to about 7.1 M, though Operating Income is likely to grow to (8.1 M).
Tharimmune income statement Correlations
Click cells to compare fundamentals
Tharimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tharimmune income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Interest Income | (246.5K) | (831.3K) | (1.6M) | 136.1K | 122.5K | 128.6K | |
| Interest Expense | 246.5K | 831.3K | 1.6M | 16.5K | 19.0K | 18.0K | |
| Selling General Administrative | 671.9K | 1.4M | 4.6M | 5.9M | 6.8M | 7.1M | |
| Other Operating Expenses | 1.5M | 3.2M | 6.9M | 9.5M | 10.9M | 11.4M | |
| Operating Income | (1.8M) | (3.2M) | (6.9M) | (9.5M) | (8.5M) | (8.1M) | |
| Net Income From Continuing Ops | (2.4M) | (2.2M) | (8.5M) | (9.3M) | (8.4M) | (8.0M) | |
| Ebit | (2.1M) | (1.6M) | (7.1M) | (9.5M) | (8.5M) | (8.1M) | |
| Research Development | 847.3K | 1.8M | 2.3M | 3.6M | 4.1M | 4.3M | |
| Ebitda | (1.9M) | (1.4M) | (6.9M) | (9.3M) | (8.4M) | (8.0M) | |
| Total Operating Expenses | 1.5M | 3.2M | 6.9M | 9.5M | 10.9M | 11.4M | |
| Income Before Tax | (2.4M) | (2.2M) | (8.5M) | (9.3M) | (8.4M) | (8.0M) | |
| Total Other Income Expense Net | (609.0K) | 1.0M | (1.6M) | 136.1K | 156.5K | 164.4K | |
| Net Income | (2.4M) | (2.2M) | (8.5M) | (9.3M) | (8.4M) | (8.0M) |
Pair Trading with Tharimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.Moving together with Tharimmune Stock
Moving against Tharimmune Stock
| 0.64 | DRTSW | Alpha Tau Medical | PairCorr |
| 0.61 | GILD | Gilead Sciences | PairCorr |
| 0.49 | PFE | Pfizer Inc | PairCorr |
| 0.45 | LLY | Eli Lilly | PairCorr |
| 0.42 | ABBV | AbbVie Inc | PairCorr |
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.